Inositol
From Wikipedia, the free encyclopedia
| myo-Inositol[1] | |
|---|---|
| IUPAC name | cis-1,2,3,5-trans-4,6 -Cyclohexanehexol |
| Other names | Cyclohexanehexol, Cyclohexitol, Dambose, Inosital, Inosite, iso-Inositol, Inositene, Inositina, i-Inositol, Inositol, MI, Meat sugar, Mesoinosit, Mesoinosite, meso-Inositol, Mesol, Mesovit, Myoinosite, Mouse antialopecia factor, Nucite, Phaseomannite, Phaseomannitol, Rat antispectacled eye factor, and Scyllite (for the structural isomer scyllo-Inositol) |
| Identifiers | |
| CAS number | |
| SMILES | O[C@H]1[C@H](O) [C@@H](O)[C@H](O) [C@H](O)[C@@H]1O |
| Properties | |
| Molecular formula | C6H12O6 |
| Molar mass | 180.16 g/mol |
| Density | 1.752 g/cm³ |
| Melting point |
225-227 °C |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
Inositol, (of which the most prominent naturally-occurring form is myo-inositol, cis-1,2,3,5-trans-4,6-cyclohexanehexol), is a carbocyclic polyol which plays an important role as the structural basis for a number of secondary messengers in eukaryotic cells, including inositol phosphates, phosphatidylinositol (PI) and phosphatidylinositol phosphate (PIP) lipids. It is found in many foods, particularly in cereals with high bran content, nuts, beans, and fruit, especially cantaloupe melons and oranges. Inositol is not considered a vitamin itself because it can be synthesised by the body.
Other naturally occurring isomers (though in minimal quantities) are scyllo-, chiro-, muco-, and neo-inositol. Other possible isomers are allo-, epi- and cis-inositol.
Myo-Inositol is classified as a member of the vitamin B complex (often referred to as vitamin B8), and is synthesized by the human body.
Contents |
The chemical formula of myo-inositol is C6H12O6. In its most stable geometry, the inositol ring is in the chair conformation. There are nine stereoisomers, all of which may be referred to as inositol; however, the natural isomer has a structure in which the 1st, 3rd, 4th, 5th and 6th hydroxyls are equatorial, while the 2nd hydroxyl group is axial.[2]
Myo-Inositol is synthesized from glucose-6-phosphate (G-6-P) in two steps. First, G-6-P is isomerised by INYNA1 to myo-inositol 1-phosphate, which is then dephosphorylated by IMPA1 to give myo-inositol.
Inositol as the basis for a number of signalling and secondary messenger molecules, is involved in a number of biological processes, including:
- Insulin signal transduction[3]
- Cytoskeleton assembly
- Nerve guidance (Epsin)
- Intracellular calcium (Ca2+) concentration control[citation needed]
- Cell membrane potential maintenance[citation needed]
- Serotonin activity modulation
- Breakdown of fats and reducing blood cholesterol[citation needed]
- Gene expression[4][5]
Some preliminary results of studies on inositol supplements show promising results for people suffering from problems such as bulimia, panic disorder and bipolar depression.
D-chiro-inositol (DCI) has been found in two double-blind studies to be an effective treatment for many of the clinical hallmarks of polycystic ovary syndrome (PCOS), including insulin resistance, hyperandrogenism and oligo-amenorrhea.[6][7] The impetuses for these studies were the observed defects in DCI metabolism in PCOS and the implication of DCI in insulin signal transduction.[8][9]
Myo-inositol has been found in double-blind studies to be an effective treatment for obsessive-compulsive disorder (OCD). It is equal in effectiveness to SSRIs and is virtually free from side effects.[10][11][12]
Animal studies suggest inositol reduces the severity of the osmotic demyelination syndrome if given prior to rapid correction of chronic hyponatraemia.[13] Further study is required prior to its application in humans for this indication.
Studies from in vitro experiments, animal studies, and limited clinical experiences, claim that inositol may be used effectively against some types of cancer, particularly when used in combination with phytic acid.[14][15]
- D-chiro-inositol
- Essential nutrient
- Inositol phosphate
- Inositol trisphosphate
- Inositol pentakisphosphate
- Inositol hexaphosphate
- Inositol triphosphate receptor
- Inositol hexanicotinate
- ^ Merck Index, 11th Edition, 4883.
- ^ S. M. N. Furse (2006). The Chemical and Bio-physical properties of Phosphatidylinositol phosphates, Thesis for M.Res.. Imperial College London.
- ^ Larner J (2002). "D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance". Int J Exp Diabetes Res 3 (1): 47–60. PMID 11900279.
- ^ (2003) "Modulation of ATP-dependent chromatin-remodeling complexes by inositol polyphosphates". Science 299 (5603): 112-4. PMID 12434013.
- ^ (2003) "Regulation of chromatin remodelling by inositol polyphosphates". Science 299 (5603): 114-6. PMID 12434012.
- ^ Nestler J E, Jakubowicz D J, Reamer P, Gunn R D, Allan G (1999). "Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome". N Engl J Med 340 (17): 1314–1320. PMID 10219066.
- ^ Iuorno M J, Jakubowicz D J, Baillargeon J P, Dillon P, Gunn R D, Allan G, Nestler J E (2002). "Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome". Endocr Pract 8 (6): 417–423. PMID 15251831.
- ^ Larner J (2002). "D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance". Int J Exp Diabetes Res 3 (1): 47–60. PMID 11900279.
- ^ Nestler J E, Jakubowicz D J, Iuorno M J (2000). "Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome". J Pediatr Endocrinol Metab 13 Suppl 5: 1295–1298. PMID 11117673.
- ^ Palatnik A, Frolov K, Fux M, Benjamin J (2001). "Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder". Journal of Clinical Psychopharmacology 21 (3): 335–339. PMID 11386498.
- ^ Fux M, Levine J, Aviv A, Belmaker RH (1996). "Inositol treatment of obsessive-compulsive disorder". American Journal of Psychiatry 153 (9): 1219–21. PMID 8780431.
- ^ Di Paolo G, De Camilli P (2006). "Phosphoinositides in cell regulation and membrane dynamics". Nature 443 (7112): 651-7. PMID 17035995.
- ^ Silver SM, Schroeder BM, Sterns RH, Rojiani AM (2006). "Myoinositol administration improves survival and reduces myelinolysis after rapid correction of chronic hyponatremia in rats". J Neuropathol Exp Neurol 65 (1): 37-44. PMID 16410747.
- ^ jn.nutrition.org
- ^ http://www.ip-6online.com/articles.html